InflaRx N.V. (IFRX) Begins Second Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis with First Patient Treated in Europe
Tweet Send to a Friend
InflaRx (NASDAQ: IFRX) today announced the treatment of the first patient in IXchange, a Phase II study with IFX-1 in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
